News
$4.5m investment for Psychae Therapeutics
We're delighted to announce a pivotal $4.5M investment from the University of Melbourne’s Genesis Pre-Seed Fund and Tin Alley Ventures into our sister company Psychae Therapeutics. This milestone was unveiled by Vice-Chancellor Duncan Maskell at the #StartedAtMelbourne Showcase and represents a vote of confidence in the mission to revolutionise mental health care through psychedelic-assisted therapies.
Psychae joins CSIRO Kick-Start Program
Psychae is excited to be working with the CSIRO Botanical Extracts Lab (BEL) via the CSIRO Kick-Start Program. This work will utilise CSIRO’s research and commercialisation expertise and state-of-the-art facilities to assist Psychae in developing novel psychedelic medicines for mental health disorders.
The Age
Psychae Co-Director A/Prof Daniel Perkins comments on the recent TGA approval for the therapeutic use of psilocybin and MDMA under the Authorised Prescriber Scheme
New Publication by the Psychae Team:
New study involving Psychae researchers reports ayahuasca to lead to rapid and large improvements in mental health among naive drinkers.
Medical Research Future Fund (MRFF) supporting Psychae Research
The Australian Government’s MRFF, provided under the 2021 Innovative Therapies for Mental Illness, will assist our researchers in conducting Australia’s first clinical trial of the use of Psychae product, a DMT-beta carboline combination, to treat Alcohol Use Disorder and Major Depressive Disorder. Our research is led by Chief Investigators and Psychae Co-Directors A/Prof Daniel Perkins and Prof Jerome Sarris, based at the University of Melbourne in collaboration with partners.
New Publication by the Psychae Team:
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Heathline
New study reports adverse physical and psychological effects from ayahuasca use are generally not severe.
TGA
Read the systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions by the TGA’s Independent Expert Panel.
Forbes
First-Ever Study Looks At Ayahuasca’s Impact On DNA Expression
The Guardian
‘Psychedelics renaissance’: new wave of research puts hallucinogenics forward to treat mental health
Ayahuasca alcohol & drug use
A newly published paper by Psychae research academics has reported that drinking ayahuasca is linked with lower current consumption of alcohol and a range of other recreational drugs
MDMA-PTSD phase 3 evidence
The first phase 3 clinical trial evidence for the use of MDMA for treatment resistant PTSD was recently published in the prestigious journal Nature Medicine, with the authors concluding that MDMA-assisted therapy is highly efficacious in individuals with severe PTSD